ARGNF (argenx SE) Accounts Payable: $718 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARGNF argenx SE ARGNF
71 GF Score
Price $865.00
GF Value $1,381.51
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is argenx SE Accounts Payable?

argenx SE ARGNF -7.52% 71 Accounts Payable is $718 Mil as of Jun. 2026. GuruFocus rates ARGNF with a GF Score™ of 71/100 and a GF Value™ of $1,381.51 (Significantly Undervalued). The stock has 4 warning signs investors should review.

argenx SE's Accounts Payable for the quarter that ended in Jun. 2026 was $718 Mil.

argenx SE's quarterly Accounts Payable declined from Dec. 2025 ($554 Mil) to Mar. 2026 ($0 Mil) but then increased from Mar. 2026 ($0 Mil) to Jun. 2026 ($718 Mil).

argenx SE's annual Accounts Payable increased from Dec. 2023 ($246 Mil) to Dec. 2024 ($342 Mil) and increased from Dec. 2024 ($342 Mil) to Dec. 2025 ($554 Mil).

argenx SE Accounts Payable Historical Data

* Premium members only.

The historical data trend for argenx SE's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Accounts Payable Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.85 188.72 245.56 342.23 554.27

argenx SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 531.97 0.00 554.27 0.00 718.00
ARGNF
71GF Score
argenx SE ARGNF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $718 Mil mean?
argenx SE (ARGNF) has a Accounts Payable of $718 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on argenx SE and its competitors.
Is argenx SE's Accounts Payable too high?
argenx SE's current Accounts Payable is $718 Mil. Overall, argenx SE has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Accounts Payable compare to VRTX and REGN?
argenx SE's Accounts Payable of $718 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on argenx SE and its competitors. argenx SE's current Accounts Payable is $718 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,381.51, compared to a current price of $865.00 — trading 37.4% below its estimated fair value. The current Accounts Payable is $718 Mil. argenx SE's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For argenx SE (ARGNF), the current Accounts Payable is $718 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGNF) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $865.00 is trading 37.4% below its estimated GF Value™ of $1,381.51. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGNF:

  • Accounts Payable: $718 Mil
  • GF Value™: $1,381.51 vs. price of $865.00 (37.4% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the ARGNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
71GF Score

Get the complete analysis for ARGNF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$865.00
Price
$1,381.51
GF Value